Table 5.
Scheme for quantitative PET reporting
| Administrative data | |
| • Hospital name, including department, address, contacts | |
| • Study identification number | |
| Patient-specific information | |
| • Patient identification, including personal data, sex, date of birth, height, weight, patient code and archive number | |
| • Relevant history, including risk factor profile, previous cardiac events, prior revascularisation procedures, symptoms and current medications | |
| • Indication for the study and specific clinical question to be answered by the investigation | |
| Study-related data | |
| • Type of study | |
| • Study date | |
| • Interpretation date | |
| • Radiopharmaceutical, injected activity at rest and at stress, type of stress agent | |
| • Acquisition protocol including description of dynamic parameters and framing of the gatedstudy | |
| • Rest blood pressure and heart rate | |
| • ECG at baseline | |
| • Peak stress blood pressure and heart rate | |
| • Presence of symptoms and ECG changes during the stress test | |
| • Quality assessment of the acquired images | |
| • Description of the processing software and compartmental model applied to the quantitative analysis | |
| Image reporting | |
| • Image description with visual analysis of resting and stress images, whenever available,with reference on the 17-segment model for territory identification | |
| • Scoring of the 17-segment model, with calculation of SRS, SSS and SDS (not for [15O]water) | |
| • Definition of the perfusion normality vs. abnormality according to the accepted criteria taking care to assign the perfusion defects to the related coronary territory, according to the standard distribution or to the patient coronary distribution pattern if known | |
| • Normal SSS = 0–3 (< 5% myocardium); mildly abnormal SSS = 4–7 (5–10% myocardium) moderately or severely abnormal SSS > 8 (> 10% myocardium) (not for [15O]water) | |
| • Visual estimate of LV dimensions and transient ischaemic dilation | |
| • Abnormal visualisation of the right ventricle and its possible enlargement | |
| • Extracardiac findings, such as abnormal lung uptake (not for [15O]water) | |
| Quantitative analysis | |
| • Resting MBF (corrected for the rate pressure product if the resting heart rate and/or the baseline blood pressure is abnormally elevated) with range of the segmental values and both the single territory values and the global left ventricular value | |
| • Stress MBF, described as above | |
| • MFR described as above | |
| • Summary of findings in term of segments/territories with peak MBF/MFR below the normal threshold (identified according to the tracer and the model used for data analysis) | |
| Gated PET acquisition | |
| • Resting LV volumes, EF and wall motion abnormalities, to be described qualitatively and scored with a proper point-scale in terms of motion and thickening according to the standard 17-segment scheme | |
| • Stress LV volumes, EF and wall motion abnormalities, to be described qualitatively and scored with a proper point-scale in terms of motion and thickening according to the standard 17-segment scheme | |
| • LVEF reserve | |
| CT (images of adequate quality) | |
| • Evaluation of coronary artery calcium scoring (description) and Agatston score; description of abnormal extracardiac findings on the CT | |
| Hybrid PET/CCTA | |
| • Correlation between MBF and the main findings of the CCTA (e.g. location of significant coronary obstructive disease and downstream MBF) | |
| Conclusion | |
| • Clinical interpretation of visual findings, MBF and MFR and gated PET data (whenever applicable) | |
| • Specific answer to the clinical question, and if needed recommendation for additional imaging |